2022, Number 2
Infective endocarditis following transcatheter aortic valve replacement with SAPIEN 3 prosthetic valve
Full text
10.35366/105823
Language: English
References: 9
Page: 78-81
PDF size: 152.59 Kb.
ABSTRACT
Infective endocarditis in native valves or in surgically replaced valves has been widely reported in the literature; however, it is still in a continuous process of investigation regarding infective endocarditis in transcatheter bioprosthetic valves. We present the case of a 66-year-old female patient with the diagnosis of early infective endocarditis (IE) of percutaneous prosthetic aortic valve SAPIEN 3 who had a favorable clinical evolution and outcome with conservative treatment with antibiotics despite that in-hospital mortality incidence due to IE-TAVR, represents > 40%. The report of new cases with their different characteristics, various treatments and results obtained, is considered of great importance to support the diagnosis and medical care for future patients.INTRODUCTION
Infective endocarditis in native valves or in surgically replaced valves has been widely reported in the literature; however, it is still in a continuous process of investigation regarding infective endocarditis in transcatheter bioprosthetic valves since these have relatively little time to be approved for international use. The echocardiogram is currently the main diagnostic tool for endocarditis; however, identifying endocarditis in biological prosthetic valves is complicated —even in expert hands— due to the characteristics that it has, such as metal struts, which prevent adequate visualization of its leaflets.1
CASE PRESENTATION
We present the case of a 66-year-old female patient with a diagnosis of early infective endocarditis (IE) of percutaneous prosthetic aortic valve SAPIEN 3, who began with an ischemic cerebral vascular event, corroborated by studies of cabinet and laboratory. Her medical history of relevance included six months with the diagnosis of diabetes mellitus, arterial hypertension that was diagnosed a year before, frailty and partial dependency as a geriatric syndrome, also with the diagnosis of chronic systolic heart failure with mildly reduced ejection fraction (44%) and severe aortic valve stenosis. Her echocardiogram reported AVA (aortic valve area) 1 cm2, a peak velocity of 4.39 m/s and a mean gradient of 65 mmHg. The patient was attended by replacement with a biological aortic prosthetic SAPIEN type transcatheter, with no incidents during the procedure.
Her condition began nine months later, with clinical data of neurological deficit characterized by hemiparesis and sensitive loss of the left part of the body, together with dyslalia and dysarthria, with loss of sphincter control, so she decided to visit medical emergencies for an evaluation. During the admission, the patient presented the same neurological alterations, and physical examination identifies a mid-systolic expulsive of grade II in aortic focus without irradiation to neck vessels, hemodynamically stable, no breathing difficulty and fever of 39 oC. Within the diagnostic protocol performed on the patient —blood cultures and echocardiogram— magnetic resonance imaging (MRI) revealed hyperintensity zone in T2 Flair (Figure 1) and four positive blood cultures with Streptococcus mitis (predominant microorganism in endocarditis after transcatheter aortic valve replacement (TAVR) isolation.2,3
The transesophageal echocardiogram in mode 2D and 3D showed three little masses suggestive of vegetations in the aortic prosthetic valve. In the image (Figure 2), a small and mobile mass is observed (black arrow) about 2 × 2 mm on the ventricular side of the prosthetic aortic valve, at the level of prosthetic discs that are not commonly seen clearly, due to interposition of the valve stent/struts.1
The third and fourth images of the 3D transesophageal echocardiogram seen at 130 degrees (Figure 3) show other pedunculated and mobile masses on the arterial side of the aortic prosthetic, suggestive of vegetations (black arrow) of 3 × 2 and 5 × 3 mm (area 0.2 cm2).
Before the procedure, the protocol for the eradication of septic foci was followed (dental evaluation, negative nasal and otic cultures) without identifying sites of active infection. During three weeks, antibiotic treatment —vancomycin and ceftriaxone— was given, coursing a favorable clinic evolution, with no fever, negative blood cultures at the ten days of treatment, without new episodes or data of neurologic or cardiac fail. It was decided that the patient left the hospital to continue with the same intravenous treatment for three weeks, with a follow-up of external consultation.
DISCUSSION
The incidence of infective endocarditis after TAVR continues to be low, with ranges of 0.5 to 3% within the first year4,5 and up to 5.8% at five years of follow-up,6 being more frequent the in-hospital post-TAVR infective endocarditis, with 0.3%.2 However, in-hospital mortality due to IE-TAVR represents a high incidence of > 40%2-4 developing as main complications fever, heart failure and systemic embolism4 and, as reported in the present case, Streptococcus mitis as one of the main causative microorganisms.7
The mobility, size, number of masses and adherence —specifically to the prosthesis leaflets— are characteristics that may imply a high risk of detachment and development of septic embolism as a complication. These characteristics are frequently described in the Edwards SAPIEN valve.1
In-hospital mortality and all-cause mortality from IE-TAVR occurred in 46% of patients in the analyzes of the partner studies. Although the rates of endocarditis after TAVR remain low, the infectious consequences are catastrophic, with high numbers in mortality after diagnosis.3 Despite the fact that the mortality rate of infective endocarditis in TAVR is high (> 40%),2,4 this case did not have a fatal end, with the established conservative measures, having a favorable clinical evolution different from that described in the literature where it is reported that mortality is higher with medical treatment versus surgical treatment.8,9
The use of third-generation cephalosporin associated with a glycopeptide showed excellent results. Streptococcus mitis has demonstrated in vitro susceptibility to this combination, and by allowing shorter treatment regimens, bacterial resistance and adverse effects such as nephrotoxicity are reduced.7 Although various risk factors associated with prosthetic valve endocarditis such as cirrhosis, pulmonary disease or chronic kidney disease have been described.4 The range of factors that influence early and/or late complications of TAVR are still to be studied, especially of the infectious type (such as the isolation of different germs and their effective treatment), the previous techniques, during the intervention and/or post-surgery care. For this reason, the exploration and reporting of cases with their different characteristics, various treatments and results obtained, is considered of great importance to support the diagnosis and medical care for future patients.
CONCLUSIONS
In the short time since one of the best treatments for valve replacement has been implemented, the factors that influence early or late complications of TAVR have yet to be described; mainly, of the infectious type such as the isolation of different germs, previous techniques and their treatment during the intervention or post-surgery care.
REFERENCES
AFFILIATIONS
1 Resident Doctor the Cardiology and Cardiovascular Surgery Service. Toluca Medical Center, ISSEMYM, Lic. Arturo Montiel Rojas. Mexico State. Mexico.
2 Specialist in Cardiology and Internal Medicine. Investigator and Clinical Advisor. Head of the Cardiology and Cardiovascular Surgery Service. Toluca Medical Center, ISSEMYM, Lic. Arturo Montiel Rojas. Mexico State. Mexico.
3 Interventional Cardiologist, Investigator and Clinical Advisor in Interventional Cardiology. Toluca Medical Center, ISSEMYM, Lic. Arturo Montiel Rojas. Mexico State. Mexico.
4 Interventional Cardiologist, Professor of the High Speciality in Interventional Cardiology. Toluca Medical Center, ISSEMYM, Lic. Arturo Montiel Rojas. Mexico State. Mexico.
5 Master of Higher Education. Researcher and Methodological Advisor. Data Manager ConsulMed. Mexico City. Toluca Medical Center, ISSEMYM, Lic. Arturo Montiel Rojas. Mexico State. Mexico.
Funding/support: No financial support was received for this study.
Declaration of interests: The authors declare no conflict of interest.
CORRESPONDENCE
Norma Eloisa Morales-Bernal. E-mail: elisusumb@hotmail.comReceived: 25/11/2021. Accepted: 24/03/2022